Skip to main content
TipRanks
Go Ultimate75% OFF

Amneal Pharmaceuticals (2DT) AI Stock Analysis

2 Followers
DE:2DT

Amneal Pharmaceuticals

(Frankfurt:2DT)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Diversified, integrated pharmaceutical modelA multi-segment portfolio gives Amneal several revenue engines across volume-driven generics, branded therapies and biosimilars. Its integrated development and manufacturing capabilities can support product control, commercialization breadth and a more durable platform for launching medicines across markets.
Negative Factors
High balance-sheet leverageAmneal’s debt-heavy capital structure leaves less financial flexibility if operating performance weakens or integration takes longer than expected. High leverage can also constrain investment choices and make interest, refinancing and acquisition-related obligations more important to the company’s long-term execution.

Amneal Pharmaceuticals (2DT) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%100%DE:2DT+89.22%EWG+3.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.45B
Dividend Yield
―
Average Volume (3M)
101
Price to Earnings (P/E)
49.7
Beta (1Y)
0.71
Revenue Growth
3.60%
EPS Growth
2761.42%
Country
Germany
Employees
8,700
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medic...

Amneal Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:2.12%|Next Earnings Date:Feb 26, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by double-digit Q3 revenue, EBITDA, and EPS growth; raised 2026 guidance; continued specialty-brand momentum; the completed Kashiv transaction; expanding biosimilar, complex-generic, manufacturing, and GLP-1 platforms; and a favorable 2027-2030 growth outlook. The main negatives were the expected AvKARE revenue decline, lower operating cash flow guidance due to inventory and collection timing, and temporarily higher leverage following the acquisition.

Positive Updates

Strong Third-Quarter Financial Performance
Q3 revenue was $863 million, up 10%; adjusted EBITDA was $207 million, up 30%; and adjusted EPS was $0.26, up 53%. Amneal said 2026 marks its seventh consecutive year of top- and bottom-line growth.

Negative Updates

AvKARE Revenue Decline
AvKARE revenue was $165 million in Q3, down 17%, due to the non-repeating nature of a large product introduction in the third quarter of last year, when revenue grew 25%. Management said revenue was stable excluding that factor.

Company Guidance

Amneal increased full-year 2026 guidance to revenue of $3.15 billion to $3.25 billion, adjusted EBITDA of between $800 million and $815 million, adjusted EPS of $1.04 and $1.08, and operating cash flow of $325 million-$375 million; it expects to finish 2026 at 3.6x adjusted EBITDA, remain below 3x adjusted EBITDA by 2028, and deliver continued high growth in 2027 and beyond. Lanreotide revenue was about $7 million in Q3, with multiple times of that expected in Q4 and a targeted 30%-40% market share; the 60 mg and 90 mg strengths are expected to launch in the second half of next year. XOLAIR is expected to launch in second half next year, towards late, while denosumab is expected in mid-next year and European lanreotide action is expected in the third quarter next year. Amneal is targeting five additional MDI and soft mist approvals over the next three years, sees a next wave of launch opportunities between 2027 and 2029, expects 2030 revenue of about $4.3 billion to $4.5 billion versus about $3.1 billion to $3.2 billion, and expects gross margins to improve further from probably about 46.5% this year versus about 45.5% last year; Pfizer construction is expected to complete in late 2028 to 2029, CREXONT is expected to perform to probably the middle part or maybe even the higher end of guidance, and BREKIYA autoinjector next year could come close to doubling performance from this year.

Amneal Pharmaceuticals Risk Analysis

Amneal Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.We may not realize the anticipated benefits of the Kashiv Acquisition, and the acquisition may increase our exposure to existing risks.Q3, 2026

Amneal Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:2DT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMPHAMPH77Outperform$1.20B12.4912.59%―3.11%-4.26%
ANIPANIP72Outperform$1.57B13.3520.00%―25.94%203.25%
RDYRDY67Neutral$12.49B41.697.37%0.75%-10.52%-55.45%
VTRSVTRS67Neutral$22.79B-37.51-4.24%2.41%4.80%82.97%
TEVATEVA65Neutral$47.15B90.756.35%―2.99%-28.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:2DTRDYVTRSTEVAANIPAMPHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:2DT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:2DTAmneal Pharma19.309.2091.09%
RDYDr. Reddy's Laboratories Ltd14.831.249.16%
VTRSViatris, Inc.19.889.5592.52%
TEVATeva Pharmaceutical Industries Limited38.5412.5448.23%
ANIPAni Pharmaceuticals69.13-11.85-14.63%
AMPHAmphastar Pharmaceuticals Inc28.111.405.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.